Literature DB >> 28412065

Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.

Thomas Seisen1, Maxine Sun1, Stuart R Lipsitz1, Firas Abdollah2, Jeffrey J Leow1, Mani Menon2, Mark A Preston1, Lauren C Harshman3, Adam S Kibel1, Paul L Nguyen4, Joaquim Bellmunt3, Toni K Choueiri3, Quoc-Dien Trinh5.   

Abstract

Given the lack of randomized evidence comparing trimodal therapy (TMT) to radical cystectomy (RC) for muscle-invasive urothelial carcinoma of the bladder (UCB), we performed an observational cohort study to examine the comparative effectiveness of these two definitive treatments. Within the National Cancer Data Base (2004-2011),we identified 1257 (9.8%) and 11 586 (90.2%) patients who received TMT and RC, respectively. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier analysis showed that median overall survival (OS) was similar between the TMT (40 mo, 95% confidence interval [CI] 34-46) and RC groups (43 mo 95% CI 41-45; p=0.3). In IPTW-adjusted Cox regression analysis with a time-varying covariate, TMT was associated with a significant adverse impact on long-term OS (hazard ratio 1.37, 95% CI 1.16-1.59; p<0.001). Interaction terms indicated that the adverse treatment effect of TMT versus RC decreased with age (p=0.004), while there was no significant interaction with gender (p=0.6), Charlson comorbidity index (p=0.09) or cT stage (p=0.8). In conclusion, we found that TMT was generally associated with worse long-term OS compared to RC for muscle-invasive UCB. However, the survival benefit of RC should be weighed against the risks of surgery, especially in older patients. These results are preliminary and emphasize the need for a randomized controlled trial to compare TMT versus RC. PATIENT
SUMMARY: We examined the comparative effectiveness of trimodal therapy versus radical cystectomy for muscle-invasive urothelial carcinoma of the bladder. We found that trimodal therapy was generally associated with worse long-term overall survival, although there may be no difference with radical cystectomy in older individuals.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystectomy; Drug therapy; Propensity score; Radiotherapy; Survival; Urinary bladder neoplasms

Mesh:

Year:  2017        PMID: 28412065     DOI: 10.1016/j.eururo.2017.03.038

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  30 in total

Review 1.  Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.

Authors:  Adnan El-Achkar; Luis Souhami; Wassim Kassouf
Journal:  Curr Urol Rep       Date:  2018-11-03       Impact factor: 3.092

2.  Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.

Authors:  Stephen B Williams; Yong Shan; Usama Jazzar; Hemalkumar B Mehta; Jacques G Baillargeon; Jinhai Huo; Anthony J Senagore; Eduardo Orihuela; Douglas S Tyler; Todd A Swanson; Ashish M Kamat
Journal:  JAMA Surg       Date:  2018-10-01       Impact factor: 14.766

Review 3.  [Radiochemotherapy for invasive bladder cancer : An update].

Authors:  N Tselis; F J Prott; O Ott; C Weiss; C Rödel
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

4.  Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.

Authors:  Herney Andrés García-Perdomo; Carlos Eduardo Montes-Cardona; Marcela Guacheta; Diego Fernando Castillo; Leonardo O Reis
Journal:  World J Urol       Date:  2018-06-25       Impact factor: 4.226

5.  Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.

Authors:  Sean A Fletcher; Sabrina S Harmouch; Marieke J Krimphove; Alexander P Cole; Sebastian Berg; Philipp Gild; Mark A Preston; Guru P Sonpavde; Adam S Kibel; Maxine Sun; Toni K Choueiri; Quoc-Dien Trinh
Journal:  World J Urol       Date:  2018-06-14       Impact factor: 4.226

Review 6.  [The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo].

Authors:  V Hechler; M Rink; D Beyersdorff; M Beer; A J Beer; V Panebianco; M Pecoraro; C Bolenz; G Salomon
Journal:  Urologe A       Date:  2019-12       Impact factor: 0.639

7.  The perils of using registry data to compare the survival and cost of radical cystectomy and trimodality therapy in bladder cancer.

Authors:  Abhishek A Solanki; Stanley L Liauw
Journal:  Transl Androl Urol       Date:  2019-12

8.  Editorial comment: understanding the cost of bladder preservation in muscle invasive bladder cancer-an evaluation of radical cystectomy versus trimodal therapy costs.

Authors:  Diana E Magee; Girish S Kulkarni
Journal:  Transl Androl Urol       Date:  2019-12

9.  Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database.

Authors:  Dharam Kaushik; Hanzhang Wang; Joel Michalek; Michael A Liss; Qianqian Liu; Richa Priya Jha; Robert S Svatek; Ahmed M Mansour
Journal:  Urology       Date:  2019-08-08       Impact factor: 2.649

10.  Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

Authors:  Stephen B Williams; Yong Shan; Mohamed D Ray-Zack; Hogan K Hudgins; Usama Jazzar; Douglas S Tyler; Stephen J Freedland; Todd A Swanson; Jacques G Baillargeon; Jim C Hu; Sapna Kaul; Ashish M Kamat; John L Gore; Hemalkumar B Mehta
Journal:  JAMA Surg       Date:  2019-08-21       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.